18 active not recruiting, 16 recruiting, 3 completed, 3 not yet recruiting. 28 Phase 2, 16 Phase 1, 7 Phase 3.
Follow amivantamab: new trials by email Literature Review of amivantamab trials Research Report on amivantamab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Amivantamab in Patients With Metastatic/Recurrent Penile Squamous Cell Carcinoma Amivantamab - Penile Squamous Cell Carcinoma, Metastatic Penile Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Latin American Cooperative Oncology Group | 58 | 2026-11-01 | 2026-09-14 |
| JIN-A02 Plus Amivantamab in EGFR-Mutant NSCLC After Third-Generation EGFR-TKI Failure JIN-A02 in Combination with Amivantamab - Carcinoma, Non-Small-Cell Lung | Phase 1 | Not yet recruiting | Yonsei University | 36 | 2026-09-28 | 2026-09-02 |
| A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC Amivantamab, Lazertinib, Carboplatin - Carcinoma, Non-Small-Cell Lung | Phase 2 | Recruiting | Janssen Research & Development, LLC | 68 | 2026-07-28 | 2026-09-25 |
| Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System Amivantamab and Recombinant Human Hyaluronidase, Biospecimen Collection, Cetuximab - Locally Recurrent Skin Squamous Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 86 | 2026-03-23 | 2026-10-15 |
| A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer Amivantamab, Olomorasib - Carcinoma, Non-Small-Cell Lung | Phase 1 / Phase 2 | Recruiting | Janssen Research & Development, LLC | 60 | 2026-03-03 | 2026-09-25 |
| A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer Amivantamab, Pembrolizumab, Carboplatin - Squamous Cell Carcinoma of Head and Neck | Phase 3 | Recruiting | Janssen Research & Development, LLC | 500 | 2025-12-03 | 2026-09-25 |
| Phase II Trial of Amivantamab Plus Monochemotherapy in Platinum Unfit NSCLC Patients With EGFR exon20 Insertion Mutations. Amivantamab - Metastatic NSCLC - Non-Small Cell Lung Cancer | Phase 2 | Recruiting | Fondazione Ricerca Traslazionale | 33 | 2025-12-02 | 2026-02-06 |
| A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors JNJ-95437446, Amivantamab - Advanced Stage Solid Tumors | Phase 1 | Recruiting | Janssen Research & Development, LLC | 400 | 2025-07-15 | 2026-09-29 |
| An Open-label, Single-arm, Multicenter Phase II Study to Evaluate the Efficacy of Amivantamab in Combination With FOLFIRI as a Second-line Treatment in Patients With RAS/BRAF Wild-type Advanced Colorectal Cancer Progressing on Prior Anti-EGFR Based Treatment. Amivantamab + FOLFIRI - RAS/BRAF Wild-type Advanced Colorectal Cancer Patients | Phase 2 | Not yet recruiting | Yonsei University | 85 | 2025-05-01 | 2025-03-04 |
| ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC ORIC-114 Dose 1 + amivantamab, ORIC-114 Dose 2 + amivantamab, ORIC-114 Dose 3 + amivantamab - Solid Tumors, EGFR Exon 20 Insertion Mutations | Phase 1 | Recruiting | ORIC Pharmaceuticals | 76 | 2025-02-27 | 2026-04-24 |
| A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Amivantamab, Lazertinib, Chemotherapy: Pemetrexed - Carcinoma, Non-Small-Cell Lung | Phase 2 | Recruiting | Janssen Research & Development, LLC | 480 | 2024-12-16 | 2026-09-25 |
| A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy Amivantamab, Cetuximab, Bevacizumab - Colorectal Neoplasms | Phase 3 | Recruiting | Janssen Research & Development, LLC | 700 | 2024-12-12 | 2026-09-25 |
| Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial) Amivantamab, Biospecimen Collection, Computed Tomography - Lung Non-Small Cell Carcinoma | Phase 2 | Recruiting | SWOG Cancer Research Network | 88 | 2024-11-19 | 2026-10-09 |
| A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer Amivantamab, Cetuximab, 5-fluorouracil - Colorectal Neoplasms | Phase 3 | Recruiting | Janssen Research & Development, LLC | 1000 | 2024-10-18 | 2026-09-25 |
| 5G-EMERALD: Amivantamab in Malignant Brain Tumours Amivantamab - Malignant Primary Gliomas, Glioblastoma Multiform (Grade IV Astrocytoma) | Phase 1 | Active not recruiting | Institute of Cancer Research, United Kingdom | 12 | 2024-10-09 | 2026-08-17 |
| A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer Amivantamab, Docetaxel - Carcinoma, Non-Small-Cell Lung | Phase 1 / Phase 2 | Completed | Janssen Research & Development, LLC | 12 | 2024-07-23 | 2026-07-31 |
| PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer Amivantamab, Tepotinib - Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 3 | 2024-06-18 | 2026-09-11 |
| A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies KQB198, Osimertinib, Amivantamab - Solid Tumor, Adult | Phase 1 | Active not recruiting | Kumquat Biosciences Inc. | 92 | 2024-06-03 | 2026-09-02 |
| A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer Amivantamab, Pembrolizumab, Paclitaxel - Squamous Cell Carcinoma of Head and Neck | Phase 1 / Phase 2 | Recruiting | Janssen Research & Development, LLC | 287 | 2024-04-22 | 2026-09-25 |
| Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib Amivantamab IV, Amivantamab SC, Lazertinib - Carcinoma, Non-Small-Cell Lung | Phase 2 | Active not recruiting | Janssen Research & Development, LLC | 305 | 2024-02-16 | 2026-09-25 |
Showing 20 of 44. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (24) · Colorectal Neoplasms (5) · Squamous Cell Carcinoma of Head and Neck (2) · Breast Neoplasms (1) · Carcinoma (1) · Carcinoma, Adenoid Cystic (1) · Carcinoma, Hepatocellular (1) · Esophageal Neoplasms (1) · Glioblastoma (1) · Head and Neck Neoplasms (1) · Lung Neoplasms (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1)
Janssen Research & Development, LLC (23) · Latin American Cooperative Oncology Group (2) · Memorial Sloan Kettering Cancer Center (2) · Yonsei University (2) · AstraZeneca (1) · ETOP IBCSG Partners Foundation (1) · Fate Therapeutics (1) · Fondazione Ricerca Traslazionale (1) · Gruppo Oncologico del Nord-Ovest (1) · Institute of Cancer Research, United Kingdom (1) · Janssen Pharmaceutical K.K. (1) · Kumquat Biosciences Inc. (1) · M.D. Anderson Cancer Center (1) · National Cancer Institute (NCI) (1) · ORIC Pharmaceuticals (1)
United States (31) · Spain (22) · South Korea (21) · France (18) · Italy (18) · China (17) · United Kingdom (17) · Taiwan (16) · Germany (15) · Brazil (13) · Japan (13) · Malaysia (12) · Canada (11) · Poland (11) · Turkey (Türkiye) (11)
Erin Schenk, MD, PhD (1) · Fernando Cotait Maluf (1) · Fernando Sabino (1) · Filippo Pietrantonio, MD (1) · Helena Yu, MD (1) · Jordi Rodon, MD (1) · Juanita Lopez, MD, PhD (1) · Paul L Swiecicki (1) · Pratik S. Multani, MD, MS (1) · Ross Soo, MD FRACP (1)
PMID 34339261, PMID 34339292, PMID 34911336, PMID 35963523, PMID 36652175, PMID 37022784, PMID 37589131, PMID 37710001, PMID 37870976, PMID 38857463, PMID 38924756, PMID 39033692, PMID 39755170, PMID 39864547, PMID 39918363, PMID 40383434, PMID 40617394, PMID 40922529, PMID 40923797, PMID 40923969, PMID 41139066, PMID 41184595, PMID 41259729, PMID 41671628, PMID 41746627, PMID 42013403, PMID 42192224, PMID 42218660, PMID 42635093, PMID 42833236, PMID 42870814
2023 (10), 2025 (3), U10CA180888 (2), 2017 (1), 2018 (1)